NeuroPace Inc Stock News

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S) application to the U.S. Food and Drug Administration (FDA) seeking to expand the labeled indication for its RNS® System to include patients with antiseizure-med...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of preliminary 18-month safety and effectiveness results from its ongoing NAUTILUS1 trial evaluating the RNS® System as an adjunctive therapy for the treatment ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be prominently featured at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia where NeuroPace will feature new clinical and AI-driven advances...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicare reimbursement updates for the RNS® System under both the CY 2026 OPPS and Medicare PFS final rules. In the CY 2026 Medicare PFS final rule, the Centers for Medicare & Medicaid Services (CMS) sign...

NeuroPace, Inc. ( NPCE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Scott Scaper Joel Becker - CEO, President & Director Patrick Williams - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Chase & Co, Research Division Priya Sachdeva - UBS Investment Bank, Research Division Michael Kratky - Leerink Partners LLC, Research Division Frank Tak...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the third...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2025 Healthcare Conference, on Wednesday, Septe...